A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Conditions
- Multiple Myeloma
- Myeloma
- Myeloma Multiple
Interventions
- DRUG: Cohort A1 & A2: KTX-1001
- DRUG: Cohort B1 & B2: KTX-1001+Mezigdomide
- DRUG: Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)
- DRUG: Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)
Sponsor
K36 Therapeutics, Inc.
Collaborators